Grünenthal Acquires Partial Rights to Nexium, Vimovo from AstraZeneca for Up-to-$922M
Grünenthal has agreed to acquire AstraZeneca's European rights to Nexium®(esomeprazole) and the pharma giant’s rights to Vimovo® (naproxen/esomeprazole) worldwide except the U.S. and Japan...
Parkinson’s Disease Drug That Cools “Brains on Fire” Could Enter Human...
Researchers at the University of Queensland in Australia have identified a small molecule that can stop the progression of Parkinson’s disease (PD) and improve...
Zika’s Balloon Popped by Peptide Needle
A new antiviral drug candidate attacks the Zika virus where it may be most vulnerable—the lipid membrane, which envelopes Zika’s RNA payload. The drug...
Conjoined Cells Form a Potent Immunotherapy Combo
Shackled together, stem cells and platelets may help us escape cancer, report UCLA scientists. In the scientists’ new study, the cancer is leukemia, and...
Custom Manufacturing Accelerates Time to Market
As the life science industry faces increasing competition—as well as global regulatory and pricing pressures—outsourcing portions or all of manufacturing is becoming increasingly prevalent....
Pergamum and Cadila Collaborate on Novel Therapy for Infections
Pergamum agreed to collaborate with Cadila Pharmaceuticals to develop a new treatment for infections based on a novel targeting mechanism that is different from classical antibiotic therapy.
Targeting Glioblastoma by Depriving Brain Cancer Cells of Cholesterol
Study identified a metabolic vulnerability in the aggressive and incurable brain cancer glioblastoma and shown how it can potentially be exploited for therapy.
Cell Therapy Manufacturing: The Supply Chain Challenge
The success of cell therapies hinges on not only proving that a product elicits the desired biological response, but also overcoming the challenges of manufacturing and administering a complex product to any patient.
Win More Biologics Development Battles with Early Stability Analysis
Sponsor: Unchained Labs
